Drug Discovery Alliance Established for Respiratory Diseases
By BiotechDaily International staff writers
Posted on 07 Mar 2012
Evotec, AG (Hamburg, Germany) and IR Pharma (Sittingbourne, Kent, UK) have entered into a strategic alliance to provide integrated drug discovery solutions to pharmaceutical and biotech companies in the field of respiratory diseases.
This alliance expands Evotec’s drug discovery platform into the field of respiratory diseases through IR Pharma’s expertise in in-vitro and in vivo respiratory pharmacology. As part of this collaboration, Evotec now can offer fully integrated respiratory and inflammation focused drug discovery programs to its partners, from target to nomination of preclinical development candidates.
Dr. Mario Polywka, chief operating officer at Evotec AG, commented, “We are looking forward to partner with IR Pharma and are excited about the potential of this alliance. IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models and coupled with our world leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas. This cooperation is a significant addition to our strategy to offer the most comprehensive drug discovery solutions to our partners.”
Prof. Maria Belvisi, director at IR Pharma, Ltd., added, “We are delighted to join forces with Evotec and firmly believe that together, we will provide efficient and innovative drug discovery solutions to our partners. We have a range of highly validated models, focusing on asthma, cough, and chronic obstructive pulmonary disease [COPD], which ideally complement Evotec’s platform, thus enabling a fully integrated approach to drug discovery in this challenging area.”
No financial details of the collaboration were disclosed.
IR Pharma provides the pharmaceutical industry with respiratory pharmacology preclinical drug discovery through short, focused projects and larger, wide-ranging system-based discovery programs.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. The company operates worldwide providing stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The company assembles top-class scientific experts and integrating state-of-the-art technologies as well as experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases, oncology, and inflammation.